Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.03. | PHARMANUTRA S.P.A.: SUCROSOMIAL IRON MENTIONED IN THE GUIDELINES OF THE "WORLD HEALTH ORGANISATION" | 220 | PR Newswire | THE GROUP'S PATENTED AND DESIGNED SOLUTION INDICATED AS THE ONLY ORAL IRON FOR ANAEMIA IN PEOPLE WITH CARDIOVASCULAR DISEASE AND DIABETES
PISA, Italy, March 25, 2025 /PRNewswire/ --... ► Artikel lesen | |
26.11.24 | PHARMANUTRA S.P.A.: DISTRIBUTION AGREEMENT FOR SIDERAL PRODUCTS SIGNED IN CANADA | 336 | PR Newswire | The contract signed with Sigma Lifesciences consolidates the presence of the Italian company in North America, where its subsidiary PharmaNutra USA Corp. is already active
PISA, Italy... ► Artikel lesen | |
30.10.24 | Pharmanutra S.p.a.: Agreement With An International Advisor In Order To Define A Development Plan For Pharmanutra Usa | 1 | CNW | ||
27.06.24 | Pharmanutra S.p.A.: The Distribution Of Iron-based Dietary Supplements Kicks Off In Mexico | 346 | PR Newswire | Partner SMS Pharma will market the three products in the SiderAL® line under the trade name Sucrosom®, which is based on our ground-breaking, patented Sucrosomial® Technology.
PISA, Italy, June... ► Artikel lesen | |
PHARMANUTRA Aktie jetzt für 0€ handeln | |||||
06.05.24 | Dividendenbekanntmachungen (06.05.2024) | 9.710 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEROPORTO GUGLIELMO MARCONI DI BOLOGNA S ... IT0001006128 - 0,264 EUR ALERION CLEANPOWER SPA IT0004720733 - 0,61 EUR ARCHROCK INC US03957W1062 0... ► Artikel lesen | |
24.04.24 | Pharmanutra S.p.A.: Sucrosomial® Technology Arrives In United States | 470 | PR Newswire | PISA, Italy, April 24, 2024 /PRNewswire/ -- 2024 is a year of great expectations for the newly established PharmaNutra USA Corp, a US company based in Florida, wholly owned by PharmaNutra S.p.A.... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ELI LILLY | 739,30 | +12,41 % | BREAKING: Eli Lilly hebt ab - Daten zu Anti-Fett-Pille - Novo Nordisk unter Druck | Der US-Pharmakonzern Eli Lilly hat die mit Spannung erwarteten Phase-3-Studiendaten (ACHIEVE-1) zu seinem oral verfügbaren Adipositas-Wirkstoffkandidaten Orforglipron veröffentlicht. Die Daten finden... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
COLLEGIUM PHARMACEUTICAL | 23,800 | +1,71 % | Collegium Pharmaceutical, Inc.: Collegium Provides 2025 Financial Guidance and Business Update | - Product Revenues, Net Expected in the Range of $735 Million to $750 Million - - Jornay PM® Net Revenue Expected to be in Excess of $135 Million - - Adjusted EBITDA* Expected in the Range of $435... ► Artikel lesen | |
CENTESSA PHARMACEUTICALS | 9,850 | -1,50 % | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 | Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025
ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type... ► Artikel lesen |